卡铂联合化疗治疗老年非小细胞肺癌剂量探讨  

A Study on Dose Level of Carboplatin Combined Chemotherapy in Treatment of Elder Non small Cell Lung Cancer

作　　者：殷铁军[1] 刘菁菁[1] 杨剑霞[1] 胡长耀[2] 

机构地区：[1]华中科技大学同济医学院附属同济医院综合医疗科,武汉430030 [2]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030

出　　处：《肿瘤防治研究》2004年第11期706-708,共3页Cancer Research on Prevention and Treatment

摘　　要：目的探讨老年非小细胞肺癌患者联合化疗时卡铂按AUC=5mg/ml·min(AUC,areaundertheconcentrationtimecurve)的剂量是否适宜。方法33例老年晚期非小细胞肺癌患者采用Taxol+CBP、Gemzar+CBP、NVB+CBP方案化疗,卡铂用药剂量按AUC=5的水平给药。全部患者共完成73周期化疗。每周期化疗前后对患者的化疗毒副反应及生活质量变化进行评估。结果骨髓毒副反应常见且较重,中性粒细胞出现Ⅲ/Ⅳ级副反应为47.9%(35/73)、血小板出现Ⅲ/Ⅳ级副反应为28.8%(21/73)。其余毒副反应不重。生存质量评分(依据国内肿瘤患者生存质量评分标准)平均下降6.5分。结论老年非小细胞肺癌患者联合化疗时,卡铂按AUC=5的剂量水平用药毒副反应较重,且对生存质量有不利影响,可能与剂量偏大有关。Objective Preliminarily to determine whether it was appropriate for elder patients with non small cell lung cancer to be treated by carboplatin at AUC=5 mg/ml·min level during combined chemotherapy.Methods 33 cases of elder patients with non small cell lung cancer in advanced stage had received 73 cycles combination chemotherapy. Chemotherapy schemes included Taxol+CBP,Gemzar+CBP and NVB+CBP. The dose of carboplatin was at AUC=5 mg/ml·min level (AUC, area under the concentration time curve). Side effects and quality of life were observed before and after chemotherapy.Results Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was 47.9% (35/73)and grade 3/4 of thrombocytopenia was 28.8% (21/73),however, other side effect was slight. The mean score of quality of life (on Chinese grading scores of QOL of cancer patients) had reduced 6.5 .Conclusion At AUC=5 mg/ml·min level, the hematological toxicity of carboplatin were severe and it had some disadvantage on the quality of life. The administration of carboplatin at AUC=5 level may not be appropriate for Chinese senile patient with non small cell lung cancer.

关 键 词：老年患者 非小细胞肺癌 卡铂 曲线下面积 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]